Skip to main content
SpringerLink
Log in

Colon Cancer

  • Chapter
  • First Online:
Surgical Oncology

Abstract

Colon cancer is a common disease that affects a significant number of people, both in the United States and worldwide. Surgery is the primary treatment for patients with resectable colon cancer. Laparoscopic colectomy is an acceptable alternative to open colectomy based on results that demonstrated oncologic equivalency between the two approaches. Robotic colectomy is emerging as an alternative approach, although data on its oncologic effectiveness is lacking. Optimal surgical resection requires resecting the affected bowel with at least 5 cm proximal and distal margins, ligating primary feeding vessels, harvesting at least 12 lymph nodes, and obtaining greater than a 1 mm circumferential radial margin. Adjuvant chemotherapy is the standard of care for stage III disease, although its role in stage II disease is debatable. The status of microsatellite instability (MSI) and the use of multigene arrays are helpful in identifying patients with stage II disease who might benefit from adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    PubMed  Google Scholar 

  3. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329(27):1977–81.

    PubMed  CAS  Google Scholar 

  4. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst. 1992;84(20):1572–5.

    PubMed  CAS  Google Scholar 

  5. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85(16):1311–8.

    PubMed  CAS  Google Scholar 

  6. Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case–control study among veterans. Arch Intern Med. 1995; 155(16):1741–8.

    PubMed  Google Scholar 

  7. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–71.

    PubMed  CAS  Google Scholar 

  8. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–95.

    PubMed  CAS  Google Scholar 

  9. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9): 638–58.

    PubMed  Google Scholar 

  10. Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(7): 1623–30.

    PubMed  Google Scholar 

  11. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev. 1993;15(2):499–545.

    PubMed  CAS  Google Scholar 

  12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.

    PubMed  CAS  Google Scholar 

  13. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5(1):19–27.

    PubMed  PubMed Central  Google Scholar 

  14. Mathew A, Peters U, Chatterjee N, Kulldorff M, Sinha R. Fat, fiber, fruits, vegetables, and risk of colorectal adenomas. Int J Cancer. 2004;108(2): 287–92.

    PubMed  CAS  Google Scholar 

  15. Howell MA. Factor analysis of international cancer mortality data and per capita food consumption. Br J Cancer. 1974;29(4):328–36.

    PubMed  CAS  PubMed Central  Google Scholar 

  16. Howe GR, Aronson KJ, Benito E, et al. The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case–control studies. Cancer Causes Control. 1997; 8(2):215–28.

    PubMed  CAS  Google Scholar 

  17. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119(11):2657–64.

    PubMed  CAS  Google Scholar 

  18. Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R. Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. Cancer Res. 1999;59(22):5704–9.

    PubMed  CAS  Google Scholar 

  19. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds. IARC Monogr Eval Carcinog Risk Chem Man. 1978;17:1–349.

    Google Scholar 

  20. Marques-Vidal P, Ravasco P, Ermelinda Camilo M. Foodstuffs and colorectal cancer risk: a review. Clin Nutr. 2006;25(1):14–36.

    PubMed  Google Scholar 

  21. Burkitt DP. Epidemiology of Burkitt’s lymphoma. Proc R Soc Med. 1971;64(9):909–10.

    PubMed  CAS  PubMed Central  Google Scholar 

  22. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342(16):1149–55.

    PubMed  CAS  Google Scholar 

  23. Alberts DS, Martínez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med. 2000;342(16):1156–62.

    PubMed  CAS  Google Scholar 

  24. McKeown-Eyssen GE, Bright-See E, Bruce WR, et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol. 1994;47(5): 525–36.

    PubMed  CAS  Google Scholar 

  25. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst. 1995;87(23):1760–6.

    PubMed  CAS  Google Scholar 

  26. Bonithon-Kopp C, Kronborg O, Giacosa A, Räth U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 2000;356(9238):1300–6.

    PubMed  CAS  Google Scholar 

  27. Asano T, McLeod RS. Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2002;2, CD003430.

    PubMed  Google Scholar 

  28. Sansbury LB, Wanke K, Albert PS, et al. The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol. 2009;170(5):576–84.

    PubMed  PubMed Central  Google Scholar 

  29. Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE. Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control. 2004;15(6):581–9.

    PubMed  Google Scholar 

  30. Aleksandrova K, Pischon T, Buijsse B, et al. Adult weight change and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Eur J Cancer. 2013;49(16):3526–36.

    PubMed  Google Scholar 

  31. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29–38.

    PubMed  CAS  Google Scholar 

  32. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297(21):2351–9.

    PubMed  CAS  Google Scholar 

  33. Ulrich CM, Potter JD. Folate and cancer–timing is everything. JAMA. 2007;297(21):2408–9.

    PubMed  CAS  Google Scholar 

  34. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose–response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–72.

    PubMed  CAS  Google Scholar 

  35. Jacobson JS, Neugut AI, Murray T, et al. Cigarette smoking and other behavioral risk factors for recurrence of colorectal adenomatous polyps (New York City, NY, USA). Cancer Causes Control. 1994;5(3): 215–20.

    PubMed  CAS  Google Scholar 

  36. Leufkens AM, Van Duijnhoven FJ, Siersema PD, et al. Cigarette smoking and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study. Clin Gastroenterol Hepatol. 2011;9(2):137–44.

    PubMed  Google Scholar 

  37. Schernhammer ES, Leitzmann MF, Michaud DS, et al. Cholecystectomy and the risk for developing colorectal cancer and distal colorectal adenomas. Br J Cancer. 2003;88(1):79–83.

    PubMed  CAS  PubMed Central  Google Scholar 

  38. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29): 3839–48.

    PubMed  PubMed Central  Google Scholar 

  39. Baglietto L, Jenkins MA, Severi G, et al. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol. 2006;59(2):114–24.

    PubMed  Google Scholar 

  40. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42(2):216–27.

    PubMed  Google Scholar 

  41. Bermejo F, García-López S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009;15(37): 4638–43.

    PubMed  CAS  PubMed Central  Google Scholar 

  42. Morrin MM, Farrell RJ, Raptopoulos V, McGee JB, Bleday R, Kruskal JB. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. Dis Colon Rectum. 2000;43(3):303–11.

    PubMed  CAS  Google Scholar 

  43. Halligan S, Altman DG, Taylor SA, et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology. 2005;237(3):893–904.

    PubMed  Google Scholar 

  44. Gluecker TM, Johnson CD, Harmsen WS, et al. Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology. 2003;227(2): 378–84.

    PubMed  Google Scholar 

  45. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–97.

    PubMed  CAS  Google Scholar 

  46. Ko C, Hyman NH. Surgeons SCoTASoCaR. Practice parameter for the detection of colorectal neoplasms: an interim report (revised). Dis Colon Rectum. 2006;49(3):299–301.

    PubMed  Google Scholar 

  47. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96(10):2992–3003.

    PubMed  CAS  Google Scholar 

  48. Finan PJ, Campbell S, Verma R, et al. The management of malignant large bowel obstruction: ACPGBI position statement. Colorectal Dis. 2007;9 Suppl 4:1–17.

    PubMed  Google Scholar 

  49. Langevin JM, Nivatvongs S. The true incidence of synchronous cancer of the large bowel. A prospective study. Am J Surg. 1984;147(3):330–3.

    PubMed  CAS  Google Scholar 

  50. Brahme F, Ekelund GR, Nordén JG, Wenckert A. Metachronous colorectal polyps: comparison of development of colorectal polyps and carcinomas in persons with and without histories of polyps. Dis Colon Rectum. 1974;17(2):166–71.

    PubMed  CAS  Google Scholar 

  51. Heald RJ, Bussey HJ. Clinical experiences at St. Mark’s Hospital with multiple synchronous cancers of the colon and rectum. Dis Colon Rectum. 1975;18(1):6–10.

    PubMed  CAS  Google Scholar 

  52. Compton C, Byrd D, Garcia-Aguilar J, et al. Colon and rectum. In: Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M, editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 185–201.

    Google Scholar 

  53. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

    PubMed  Google Scholar 

  54. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Surgeons SPTFotASoCaR. Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012;55(8):831–43.

    PubMed  Google Scholar 

  55. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93(8):583–96.

    PubMed  CAS  Google Scholar 

  56. Wright FC, Law CH, Last L, et al. Lymph node retrieval and assessment in stage II colorectal cancer: a population-based study. Ann Surg Oncol. 2003;10(8):903–9.

    PubMed  CAS  Google Scholar 

  57. Bateman AC, Carr NJ, Warren BF. The retroperitoneal surface in distal caecal and proximal ascending colon carcinoma: the Cinderella surgical margin? J Clin Pathol. 2005;58(4):426–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  58. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26(3):350–7.

    PubMed  Google Scholar 

  59. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol. 2001;19(18):3895–902.

    PubMed  CAS  Google Scholar 

  60. den Dulk M, Marijnen CA, Putter H, et al. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg. 2007;246(1):83–90.

    Google Scholar 

  61. Wiggers T, Jeekel J, Arends JW, et al. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg. 1988;75(5):409–15.

    PubMed  CAS  Google Scholar 

  62. Slanetz CA, Grimson R. Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer. Dis Colon Rectum. 1997;40(10):1205–18; discussion 1218–1209.

    PubMed  Google Scholar 

  63. Group COoSTS. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350(20):2050–9.

    Google Scholar 

  64. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25(21):3061–8.

    PubMed  Google Scholar 

  65. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010;97(11):1638–45.

    PubMed  CAS  Google Scholar 

  66. Buunen M, Veldkamp R, Hop WC, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009;10(1):44–52.

    PubMed  Google Scholar 

  67. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013;100(1):75–82.

    PubMed  CAS  Google Scholar 

  68. Trastulli S, Desiderio J, Farinacci F, et al. Robotic right colectomy for cancer with intracorporeal anastomosis: short-term outcomes from a single institution. Int J Colorectal Dis. 2013;28(6):807–14.

    PubMed  Google Scholar 

  69. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322(6):352–8.

    PubMed  CAS  Google Scholar 

  70. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321–6.

    PubMed  CAS  Google Scholar 

  71. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345(8955):939–44.

    Google Scholar 

  72. O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1): 246–50.

    PubMed  Google Scholar 

  73. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553–9.

    PubMed  CAS  Google Scholar 

  74. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21(15): 2896–903.

    PubMed  CAS  Google Scholar 

  75. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    PubMed  Google Scholar 

  76. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    PubMed  Google Scholar 

  77. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    PubMed  CAS  Google Scholar 

  78. Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28): 3768–74.

    PubMed  CAS  PubMed Central  Google Scholar 

  79. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.

    PubMed  CAS  Google Scholar 

  80. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25(1): 102–9.

    PubMed  CAS  Google Scholar 

  81. Marsoni S, Investigators IMPACT. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. Semin Oncol. 2001;28 Suppl 1:14–9.

    Google Scholar 

  82. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17(5):1356–63.

    Google Scholar 

  83. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806.

    PubMed  CAS  Google Scholar 

  84. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    PubMed  Google Scholar 

  85. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13(12):2936–43.

    PubMed  CAS  Google Scholar 

  86. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17(5): 1349–55.

    PubMed  CAS  Google Scholar 

  87. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17(4):959–66.

    PubMed  PubMed Central  Google Scholar 

  88. Harrington DP. The tea leaves of small trials. J Clin Oncol. 1999;17(5):1336–8.

    PubMed  CAS  Google Scholar 

  89. Wein A, Hahn EG, Merkel S, Hohenberger W. Adjuvant chemotherapy for stage II (Dukes’ B) colon cancer: too early for routine use. Eur J Surg Oncol. 2000;26(8):730–2.

    PubMed  CAS  Google Scholar 

  90. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;3, CD005390.

    PubMed  Google Scholar 

  91. O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011; 29(25):3381–8.

    PubMed  PubMed Central  Google Scholar 

  92. Mayer RJ. Reply to A. Grothey et al and R.S. Midgley et al. J Clin Oncol. 2013;31(12):1612–3.

    PubMed  Google Scholar 

  93. Buyse M, Piedbois P. Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol. 2001;28 Suppl 1:20–4.

    PubMed  CAS  Google Scholar 

  94. Mayer RJ. Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol. 2012;30(27):3325–7.

    PubMed  CAS  Google Scholar 

  95. Grothey A, de Gramont A, Sargent DJ. Disease-free survival in colon cancer: still relevant after all these years! J Clin Oncol. 2013;31(12):1609–10.

    PubMed  Google Scholar 

  96. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–60.

    PubMed  CAS  Google Scholar 

  97. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205–11.

    PubMed  CAS  Google Scholar 

  98. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–7.

    PubMed  PubMed Central  Google Scholar 

  99. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6): 2073–87.e2073.

    PubMed  CAS  PubMed Central  Google Scholar 

  100. Drescher KM, Sharma P, Lynch HT. Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol. 2010;2010:170432.

    PubMed  PubMed Central  Google Scholar 

  101. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer–a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153–62.

    PubMed  PubMed Central  Google Scholar 

  102. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol. 2010;28(3):466–74.

    PubMed  CAS  Google Scholar 

  103. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635–46.

    PubMed  CAS  Google Scholar 

  104. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91(15):1295–303.

    PubMed  CAS  Google Scholar 

  105. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006;131(3):729–37.

    PubMed  CAS  Google Scholar 

  106. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344(16): 1196–206.

    PubMed  CAS  PubMed Central  Google Scholar 

  107. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.

    PubMed  CAS  Google Scholar 

  108. O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937–44.

    PubMed  PubMed Central  Google Scholar 

  109. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29(35): 4620–6.

    PubMed  Google Scholar 

  110. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17–24.

    PubMed  Google Scholar 

  111. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.

    PubMed  Google Scholar 

  112. Yothers G, O’Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31(36):4512–9.

    PubMed  CAS  Google Scholar 

  113. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14): 1775–81.

    PubMed  PubMed Central  Google Scholar 

  114. National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (2013). Accessed 23 May 2013.

  115. Black E, Falzon L, Aronson N. Gene expression profiling for predicting outcomes in stage II colon cancer. Agency for Healthcare Research and Quality (US). 2012;13 (http://www.ncbi.nlm.nih.gov/books/NBK115808/). Accessed 25 Apr 2014.

  116. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003; 21(15):2912–9.

    PubMed  Google Scholar 

  117. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.

    PubMed  Google Scholar 

  118. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503–7.

    PubMed  Google Scholar 

  119. Willett CG, Tepper JE, Skates SJ, Wood WC, Orlow EC, Duttenhaver JR. Adjuvant postoperative radiation therapy for colonic carcinoma. Ann Surg. 1987;206(6):694–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  120. Martenson JA, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol. 2004;22(16):3277–83.

    PubMed  CAS  Google Scholar 

  121. de Santibañes E, Lassalle FB, McCormack L, et al. Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes. J Am Coll Surg. 2002;195(2):196–202.

    PubMed  Google Scholar 

  122. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57; discussion 657–648.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

 The portion of this work was supported by the Charles D. Knight, Sr. Endowed Professorship.

Author information

Authors and Affiliations

  1. Department of Surgery, Carlsbad Medical Center, 2111 Calle De Codorniz, Carlsbad, NM, 88220, USA

    Salim Amrani M.D.

  2. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C-1067, New York, NY, USA

    Michael Polcino M.D.

  3. Department of Surgical Oncology, UT MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX, USA

    Miguel Rodriguez-Bigas M.D.

  4. Department of Surgery, LSU Health Sciences Center-Shreveport, 1501 Kings Hwy, 33932, Shreveport, LA, 71130-3932, USA

    Quyen D. Chu M.D., MBA, FACS

Authors
  1. Salim Amrani M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Polcino M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Rodriguez-Bigas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Quyen D. Chu M.D., MBA, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quyen D. Chu M.D., MBA, FACS .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Amrani, S., Polcino, M., Rodriguez-Bigas, M., Chu, Q.D. (2015). Colon Cancer. In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation